Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, α-interferon (leucocyte) and tamoxifen

Autor: S. Colleen, R. Zimmerman, K. Engman, M. Helsing, Roger Henriksson, Sten Nilsson, P. Wersäll

Publikováno v: British Journal of Cancer. 77:1311-1317

Metastatic renal cell carcinoma (RCC) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::61465c7cdeb50c15d7bd65a144f9a14e
https://doi.org/10.1038/bjc.1998.218

Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study

Autor: Roger Henriksson, Ulrika Stierner, P. Wersall, Peter Naredi, K. Engman, Frede Donskov, Kristoffer Hellstrand, Hanne Marie Nellemann, H. von der Maase

Publikováno v: Donskov, F, Maase, H V D, Henriksson, R, Stierner, U, Wersäl, P, Nellemann, H, Hellstrand, K, Engman, K & Naredi, P 2002, ' Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alfa in patients with metastatic renal cell carcinoma: Results of an open, single-armed, multi-center phase II study ', Annals of Oncology, vol. 13, no. 3, pp. 441-449 . https://doi.org/10.1093/annonc/mdf049

OBJECTIVES Histamine inhibits formation and release of monocyte/macrophage-derived reactive oxygen metabolites and thereby protects natural killer (NK) and T cells against oxidative inhibition. Efficacy and safety of histamine, when given in combinat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb84c6d92a64b5e97da4ce4e197e062
https://pubmed.ncbi.nlm.nih.gov/11996477

Tolerance to long-term treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon

Autor: B, Ahren, K, Engman, A, Lindblom

Publikováno v: Anticancer research. 12(3)

We report here the long-term toleration of treatment with a highly purified human leukocyte alpha-interferon (Interferon Alfanative) in patients with midgut carcinoid tumours with liver metastases. During an 18-month period, 13 consecutive patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a415e8c3a3aacb497b8ec3e1b8bdc7d8
https://pubmed.ncbi.nlm.nih.gov/1622146

Human leucocyte interferon-α therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-α2a

Autor: K. Engman, Christer Paul, E. Törnebohm-Roche, Mats Merup

Publikováno v: European Journal of Cancer. 30:1729-1730

6. Morales A. Eidineer D. Bruce AW. Intracavitarv bacillus Calmette Guerin in treatmeit of superficial bladder Turn0rs.J Ural 1976,116, M-184. Herr HO, Laudone VP, Bad.alement BA, et al. BCG therapy alters the progression of superficial bladder cance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::326f71afad3990a81e3adbd50c28bfb7
https://doi.org/10.1016/0959-8049(94)90604-1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.